The takeaway
Novo Nordisk A/S shows a moderate seasonal pattern over 10 years of data — strongest in December (+1.6%) and softest in September (−3.6%).
Right now
In July, the stock has fallen 50% of years, averaging −2.3%, roughly 4.5 pts behind the S&P 500.
The full picture
Novo Nordisk A/S's most dependable month has been December, higher in 9 of 10 years; September has been its least reliable, up just 20% of the time.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Win rate % | ||||||||||||
| Median return % | ||||||||||||
| 2025 | ||||||||||||
| 2024 | ||||||||||||
| 2023 | ||||||||||||
| 2022 | ||||||||||||
| 2021 | ||||||||||||
| 2020 | ||||||||||||
| 2019 | ||||||||||||
| 2018 | ||||||||||||
| 2017 | ||||||||||||
| 2016 |
Month by month
The stock's clearest edge over the S&P 500 lands in August (+4.2 pts); it has trailed the market most in July (−4.5 pts).
“vs S&P” is Novo Nordisk A/S’s average for a month minus the S&P 500’s average for that same month — isolating Novo Nordisk A/S’s own seasonal edge from broad market drift.
Reality check
Over the last 5 years, December has closed higher 80% of the time versus 90% across the last 10 years — the pattern is holding.
Figures are the typical (median) December return and how often it rose — the last 5 years versus the last 10(the heatmap’s default window). This verdict stays anchored to that 10-year window even if you zoom the chart, so it never disagrees with the badges above.
In plain English
Dependability is the through-line here. December stands out, higher in 9 of 10 Decembers, but it heads a clutch of months that pull the year reliably upward.
Its average (+1.6%) and median (+3.4%) land within a hair of each other — the tell of steady, year-after-year gains rather than one outlier doing the work. Crucially, the gain is the stock's own rather than a rising tide's: December has cleared the S&P 500 by +0.6 points above the index. That consistency sets it apart from the field, where the average stock manages December only about 58% of the time.
The strength clusters rather than stands alone — November–February forms a firm stretch that carries much of the year. The weaker half of the year is plainer: September has been the soft spot — the weakest of 3 months that average a loss (−3.6%), and the edge isn't year-round — the stock has trailed the S&P 500 in July, September, and October. Its roughest month on record was a −32.6% July in 2025 — a reminder of how hard even a seasonal name can fall.
At its steadiest, December strung together 8 straight positive years. Reassuringly, the tendency has held its shape: the recent five years still track the years behind them.
The takeaway is less about when to buy than what to expect: December aside, the stock's months offer little reliable tilt.
Short answers on the stock's best month (December), its worst (September), and whether it really trades seasonally.
Yes, to a moderate degree. Since 2016 its best month (December, +1.6%) has run well ahead of its worst (September, −3.6%) — the heatmap above shows how steady that gap has been year to year.
December has been the strongest, averaging +1.6% and closing higher in 9 of 10 years since 2016.
It's the weakest, averaging −3.6% — historically a soft spot, though it still varies from year to year.
Explore
These names have the strongest July track records on record — a starting point for comparison.
Before you trade